CIK 0001357459 · Non-accelerated filer<br>Smaller reporting company
PALISADE BIO, INC.
Sign in to watch- Ticker
- PALI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522007292
- Phone
- (858) 704-4900
- Business address
- 7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
- Former names
- PALISADE BIO, INC., Seneca Biopharma, Inc., Neuralstem, Inc.
- Open-market buys, last 90 days
- $28,800
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$28,800. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-11 | Jones Mitchell Lawrence Chief Medical Officer | Option exercise | +8,000 | 15,252 | ||
| 2026-02-11 | Jones Mitchell Lawrence Chief Medical Officer | Option exercise · Restricted Stock Units | −8,000 | 16,000 | ||
| 2026-02-11 | Finley John David CEO, CFO | Option exercise | +13,333 | 31,249 | ||
| 2026-02-11 | Finley John David CEO, CFO | Option exercise · Restricted Stock Units | −13,333 | 26,667 | ||
| 2026-02-09 | Jones Mitchell Lawrence Chief Medical Officer | Grant or award · Restricted Stock Units | +787,000 | 787,000 | ||
| 2026-02-09 | Finley John David CEO, CFO | Grant or award · Restricted Stock Units | +2,011,000 | 2,011,000 | ||
| 2026-01-16 | Williams Donald Allen Director | Purchase | +5,000 | $1.67 | $8K | 10,728 |
| 2026-01-09 | Williams Donald Allen Director | Purchase | +5,000 | $1.88 | $9K | 5,728 |
| 2025-10-06 | Williams Donald Allen Director | Grant or award · Restricted Stock Units | +182,000 | 182,000 | ||
| 2025-10-06 | Wei Binxian Director | Grant or award · Restricted Stock Units | +60,600 | 60,600 | ||
| 2025-10-06 | Chuang Emil Director | Grant or award · Restricted Stock Units | +60,600 | 60,600 | ||
| 2025-10-06 | Williams Donald Allen Director | Grant or award · Restricted Stock Units | +1,538,700 | 1,538,700 | ||
| 2025-10-06 | Wei Binxian Director | Grant or award · Restricted Stock Units | +510,700 | 510,700 | ||
| 2025-10-06 | Jones Mitchell Lawrence Chief Medical Officer | Grant or award · Restricted Stock Units | +7,665,800 | 7,665,800 | ||
| 2025-10-06 | Finley John David CEO, CFO | Grant or award · Restricted Stock Units | +9,179,400 | 9,179,400 | ||
| 2025-10-06 | Chuang Emil Director | Grant or award · Restricted Stock Units | +510,700 | 510,700 | ||
| 2025-09-04 | Williams Donald Allen Director | Grant or award · Phantom Units | +64,400 | 64,400 | ||
| 2025-09-04 | Wei Binxian Director | Grant or award · Phantom Units | +18,800 | 18,800 | ||
| 2025-09-04 | Jones Mitchell Lawrence Chief Medical Officer | Grant or award · Phantom Units | +289,000 | 289,000 | ||
| 2025-09-04 | Finley John David CEO, CFO | Grant or award · Phantom Units | +323,400 | 323,400 |
Page 3 of 12 · 233 trades